We are a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (“WHO”), the U.S. Centers for Disease Control and Prevention (“CDC”) and the U.S. Food and Drug Administration (“FDA”). Priority pathogens are those which require new antibiotics to address […]

(Note: This biotech company is focused on developing synthetic psychedelic compounds to treat mental health disorders, including treatment-resistant depression, anxiety and substance abuse disorder. Billionaire Peter Thiel invested $12 million in this start-up in November 2020 through Thiel Capital, his venture capital firm, as part of a $125 million private fund-raising round, CNBC reported.)  We […]

(Note: IPOScoop has NO CALL on this deal because it is NOT an IPO. This is a NASDAQ uplisting from the SIX Swiss Exchange Ltd., where the company’s stock trades under the symbol “MOLN.” On June 8, 2021, the last reported sale price was CHF 24.40, equivalent to US$27.14.)    We are a clinical biopharmaceutical […]

We are a biotechnology company dedicated to developing treatments for certain medical conditions. Two of our programs are focused on kidney disease: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb and UNI 494 were initially developed by, and licensed to us […]

DiDi is known as China’s Uber. Principal stockholders include a SoftBank Vision Fund entity, with a 21.5 percent pre-IPO stake; an Uber entity, with a 12.8 percent pre-IPO stake, and Tencent Entities, with a 6.8 percent IPO stake. This is expected to be one of the largest tech IPOs of the year. The company recently […]

We are a preclinical biotech company. We are a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. We have assembled a world-class team, comprising some of the foremost scientific leaders in the fields of oncology and adoptive cell therapy (ACT), including Drs. Rick Klausner, Nick Restifo, Stan […]

We intend to focus our search on innovation in the logistics industry, which includes both logistics technology companies and traditional industry players that can leverage technology to improve the efficiency of customer supply chains and their markets. Alan Gershenhorn, our CEO, recently retired from his position as executive vice president and chief commercial officer of […]

Lakeshore Acquisition I Corp. is a new blank check company organized by the executives of Shanghai Renaissance Investment Management, a private equity firm in China. (Incorporated in the Cayman Islands in 2021)  We will seek to capitalize on the significant contacts and experience of our management team, including Bill Chen, our Chairman and CEO, who is […]

It is our intention to pursue prospective targets that are in the financial technology (FinTech), information technology (InfoTech), insurance technology (InsurTech) and business services sectors. We will primarily seek to acquire one or more growth businesses with a total enterprise value of between $200 million and and $600 million. (Incorporated in the British Virgin Islands) 

We intend to focus our search for business combination targets in the Travel, Leisure & Hospitality industries, including technology and data companies operating in these industries, although we may pursue an acquisition in any business industry or sector, including, without limitation, real estate-related operating, technology and investment companies. We believe that our management team is well […]